$15.47
0.06% today
Nasdaq, Aug 12, 04:38 pm CET
ISIN
US44842L1035
Symbol
HCM

Hutchison China MediTech Limited Sponsored ADR Stock price

$15.48
-0.56 3.49% 1M
+2.28 17.27% 6M
+1.07 7.43% YTD
-4.82 23.74% 1Y
+1.62 11.69% 3Y
-17.34 52.83% 5Y
+2.08 15.52% 10Y
+2.08 15.52% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.48 3.20%
ISIN
US44842L1035
Symbol
HCM
Industry

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
387.0 | 33.3
P/S
4.2 | 3.6
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$630.2m | $724.7m
EBITDA
$-31.4m | $16.3m
EBIT
$-43.7m | $22.5m
Net Income
$37.7m | -
Free Cash Flow
$-17.4m
Growth (TTM | estimate)
Revenue
-24.8% | 15.0%
EBITDA
-218.0% | 152.1%
EBIT
-337.9% | 151.5%
Net Income
-62.6% | -
Free Cash Flow
-109.3%
Margin (TTM | estimate)
Gross
44.6%
EBITDA
-5.0% | 2.3%
EBIT
-6.9%
Net
6.0% | -
Free Cash Flow
-2.8%
More
EPS
$0.0
FCF per Share
-
Short interest
0.4%
Employees
-
Rev per Employee
-
Show more

Is Hutchison China MediTech Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Hutchison China MediTech Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

24x Buy
89%
3x Hold
11%

Analyst Opinions

27 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

Buy
89%
Hold
11%

Financial data from Hutchison China MediTech Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
630 630
25% 25%
100%
- Direct Costs 349 349
9% 9%
55%
281 281
38% 38%
45%
- Selling and Administrative Expenses 113 113
15% 15%
18%
- Research and Development Expense 212 212
30% 30%
34%
-31 -31
218% 218%
-5%
- Depreciation and Amortization 12 12
50% 50%
2%
EBIT (Operating Income) EBIT -44 -44
338% 338%
-7%
Net Profit 38 38
63% 63%
6%

In millions USD.

Don't miss a Thing! We will send you all news about Hutchison China MediTech Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hutchison China MediTech Limited Sponsored ADR Stock News

Neutral
Seeking Alpha
4 days ago
HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Chig Fung Cheng - CFO & Executive Director David Ng - Head of Investor Relations & Capital Strategies George Yuan - Corporate Participant Ming Shi - Executive VP, Head of R&D and Chief Medical Officer Wei-Guo Su - CEO, Chief Scientific Officer & Executive Director Conference Ca...
Neutral
GlobeNewsWire
about one month ago
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
Neutral
GlobeNewsWire
about one month ago
— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —
More Hutchison China MediTech Limited Sponsored ADR News

Company Profile

Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.

Head office Cayman Islands
CEO Wei Su
Founded 2000
Website www.hutch-med.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today